XOMA Royalty is honored to have been placed on Forbes’ recently announced 2025 list of America’s Most Successful Small-Cap Companies.?? https://bit.ly/4fyOczo #Royalty #Royalties #Monetization #Milestones #Strategy #Aquisition #Portfolio #DrugApproval #CashFlow #Growth #Scale #RoyaltyCapitalSolutions #Forbes #Team #Dedication #Success
XOMA Royalty
生物技术研究
Emeryville，California 5,189 位关注者
We are a biotechnology royalty aggregator playing a distinctive role to help biotech companies achieve their goals.
关于我们
XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
- 网站
-
https://www.xoma.com
XOMA Royalty的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Emeryville，California
- 类型
- 上市公司
- 创立
- 1981
- 领域
- Biotechnology、Pharmaceutical、Licensing、Royalty Aggregator、Royalty Acquirer和Biotech Deals
地点
-
主要
获取路线
2200 Powell Street
Suite 310
US，California，Emeryville，94608
XOMA Royalty员工
动态
-
Owen Hughes and Brad Sitko are looking forward to another insightful and engaging conversation with H.C. Wainwright & Co., LLC's Joe Pantginis on Monday, November 18.?We invite you to join us by registering through the link below. ? #Royalty #Royalties #Milestones #MilestonePayments #RoyaltyAcquisition #AlternativeFinance Matthew Keller, Ph.D., Sara Nik, PhD, Lander Ega?a-Gorro?o, Ph.D., Joshua Korsen, PhD, Michael E. Meyers, William Hoh, Richard Gormley, John Chambers, Kira Sheinerman, PhD, MBA, Matthew Judson, Thomas Hoffmann
The management team of XOMA Royalty (NASDAQ: XOMA) will be joined by our very own Joe Pantginis for a virtual fireside chat next Monday, November 18, at 10am EST. Chief Executive Officer Owen Hughes, Chief Investment Officer Brad Sitko, and Chief Financial Officer Thomas Burns will come together to discuss the progress of XOMA’s royalty aggregation model, as well as recent transactions that have contributed to the expansion of the company’s portfolio of royalty bearing assets. Visit https://ct.to/tMxknyl to register!
-
-
Today we issued XOMA Royalty’s Third Quarter Financial Results and highlighted recent activities related to our royalty portfolio.?Owen Hughes encapsulated our year-to-date portfolio milestones and acquisition activities by saying “We continue to take a balanced approach to building a portfolio of sustainable cashflow streams by selectively acquiring royalty economics across the lifecycle of drug development.”?The full press release can be accessed here https://bit.ly/4eqoWdc ? #Royalty #Royalties #Monetization #Milestones #Strategy #Aquisition #Portfolio #DrugApproval #CashFlow #Growth #Scale #RoyaltyCapitalSolutions
-
-
Today we added 60-plus assets across 30 partners to the XOMA Royalty portfolio. Our strategic transaction with Twist Bioscience provides XOMA Royalty with a 50% economic interest in the royalties and milestones originating from Twist Biopharma Solutions.? With 6 commercial assets and 7 in Phase 3 development today, we have been working to build and scale XOMA Royalty’s future commercial asset portfolio. Brad Sitko stated, “This transaction reinforces our commitment to a disciplined capital deployment strategy and showcases our ability to create bespoke royalty capital solutions to meet the unique needs of our partners.” ?XOMA Royalty’s portfolio now has over 100 assets with milestone potential over $1 billion. You can read our press release here https://bit.ly/3BUXsPl ? #Royalty #Royalties #Monetization #Milestones #Strategy #Aquisition #Portfolio #Growth #Scale #RoyaltyCapitalSolutions
-
-
XOMA Royalty is pleased to participate in the Orrick, Herrington & Sutcliffe LLP and CBRE Global Workplace Solutions (GWS) / CBRE Life Sciences Alternative Funding Summit on Monday, October 7.?If you would like to meet with members of our business development team, please contact Brad Sitko or Nicholas A. Cole.? ? #Royalty #Royalties #RoyaltyMonetization #AltFinance?
Orrick, Herrington & Sutcliffe LLP, in collaboration with CBRE / CBRE Global Workplace Solutions (GWS) and top industry experts, is hosting the Life Sciences Alternative Financing Summit to dive into these critical opportunities. Join high-growth companies, investors, and thought leaders on Monday, Oct. 7 in San Francisco for a deep dive into the latest funding strategies shaping the future of the sector. RSVP here: https://lnkd.in/gzVzViME #LifeSciences #Healthtech #Funding #Innovation #AlternativeFinancing Jonathan Norris | Timothy Sullivan | Peter Renehan, MD | Craig Gravitz | Shirley Bergin | Misti Ushio | Nan Li | Clark Hayes | Pete Sletteland | Cristy Barnes | Norman Friedland, Esq. | Michael Boggs | Brad Sitko | Eric J. Dimise, PhD | Jennifer Friel Goldstein | Barbara White | Jenica Patterson Mike O'Donnell | Stephen Thau | Alexandra Wood | Lukas Ault | Neel Lilani HSBC Innovation Banking | SFJ Pharmaceuticals, Inc. | Apellis Pharmaceuticals | Blackstone | Advanced Research Projects Agency for Health (ARPA-H) | Digitalis Ventures | Dimension | Silicon Valley Bank | Hercules Capital | FullSky Partners | Revelation Partners | XOMA Royalty | NYSE
-
-
Holders of XOMA Royalty’s perpetual preferred shares XOMAP and XOMAO on October 3, 2024, should anticipate receiving their dividend on October 15, 2024.?Details can be found in our September 23rd press release https://bit.ly/4diXOwl ? #Dividends #DividendPayments #DividendStocks #PerpetualPreferred #XOMAP #XOMAO #Royalty
-
-
FDA’s approval of MIPLYFFA? (arimoclomol) on Friday, September 20, was a watershed moment for the Niemann-Pick disease type C (NPC) community and for Zevra Therapeutics.?MIPLYFFA? is the first FDA-approved therapy for use in patients 2 years of age and older with this ultra-rare, relentlessly progressive, degenerative, and potentially fatal disease.? XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA? sales and up to $52.6 million in milestone payments.?Our press release can be found here https://bit.ly/3XUjYk7.?More detailed information on MIPLYFFA? can be found in Zevra’s press release which is available here https://bit.ly/3XS9d1t. #NPC #NiemannPick #MIPLYFFA #arimoclomol #Royalties #Royalty #Milestones #NewDrugApproval #RareDisease?
-
-
Owen Hughes and Brad Sitko had an engaging conversation with Eric Schmidt at the 2024 Cantor Fitzgerald Global Healthcare Conference.?You can listen to the replay here - https://bit.ly/3TzLgJH ? #CantorHCC #Royalties #Royalty #Monetization #LifeSciences #Acquisition #Portfolio
-
-
Owen Hughes and Brad Sitko will present XOMA Royalty’s latest updates during the H.C. Wainwright & Co., LLC and Cantor Fitzgerald conferences.?We look forward to seeing you there!?https://lnkd.in/gd3YyFnJ ? #HCWainwrightGlobal #CantorHCC #Royalties #Royalty #Monetization #LifeSciences #Acquisition #Portfolio
-
-
Yesterday we announced XOMA’s 2Q2024 financial results, which included total cash receipts of $22.6 million, inclusive of royalty income and milestones from two partners.??Since March, there have been several significant advancements within our royalty and milestone portfolio that are the result of our partners’ commitments to bring new therapies to patients in need of treatment options.?Details are available in our press release, which you can access here https://bit.ly/4dCPsjw? ? #Royalty #Royalties #Milestones #OJEMDA #arimoclomol #RZ358 #Ersodetug?#ITP #XACIATO #DaréBio #Ovaprene #SildenafilCream #Acquisition?
-